EGFR and non-small cell lung carcinoma: In the epidermal growth factor receptor (EGFR) mutant NSCLC, it is well-known that acquired mutations, including T790M, confer AR to tumors after EGFR tyrosine kinase inhibitor (TKI) treatment9.